

Communication

Synthesis of (+)-pancratistatins via catalytic desymmetrization of benzene

Lucas W. Hernandez, Jola Pospesch, Ulrich Kloeckner, Tanner W. Bingham, and David Sarlah

J. Am. Chem. Soc., **Just Accepted Manuscript** • Publication Date (Web): 23 Oct 2017

Downloaded from <http://pubs.acs.org> on October 23, 2017

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Synthesis of (+)-pancratistatins via catalytic desymmetrization of benzene

Lucas W. Hernandez, Jola Pospech, Ulrich Klöckner, Tanner W. Bingham, David Sarlah*

Roger Adams Laboratory, Department of Chemistry, University of Illinois, Urbana, Illinois 61801, USA

Supporting Information Placeholder

ABSTRACT: A concise synthesis of (+)-pancratistatin and (+)-7-deoxypancratistatin from benzene using an enantioselective, dearomative carboamination strategy has been achieved. This approach, in combination with the judicious choice of subsequent olefin-type difunctionalization reactions, permits rapid and controlled access to a hexasubstituted core. Finally, minimal use of intermediary steps as well as direct, late stage C-7 hydroxylation provides both natural products in six and seven operations.

The plant-derived metabolites (+)-pancratistatin (**1**)¹ and (+)-7-deoxypancratistatin (**2**)² belong to a family of densely functionalized and stereochemically complex Amaryllidaceae alkaloids that are well known for their potent anticancer activity (Figure 1).³ For example, pancratistatin (**1**) showed substantial *in vivo* activity against murine P-388 lymphocytic leukemia and murine M-5076 ovary sarcoma, and reduced growth of subcutaneous colon HT-29 tumors.⁴ Moreover, experiments examining pancratistatin-induced apoptosis revealed noticeably reduced death in non-cancerous cells relative to cancer cell lines, making these compounds appealing clinical lead candidates.⁵ Finally, pancratistatins also showed significant antiviral activities, including *in vivo* models for Japanese encephalitis,⁶ a disease for which no other known small-molecule anti-infective agent exists.




Figure 1. Structures of pancratistatin (**1**) and 7-deoxypancratistatin (**2**) and their retrosynthetic analysis.

These promising biological properties made pancratistatins exceptionally attractive targets for chemical synthesis.^{7,8} Nevertheless, despite numerous impressive efforts, only milligram quantities of pancratistatins have been prepared to date. Herein, we report a scalable and concise synthesis of (+)-pancratistatin (**1**) and (+)-7-deoxypancratistatin (**2**) from benzene (**3**) using a dearomative functionalization approach. Using this strategy, benzene can be seen as a surrogate for the hypothetical 1,3,5-cyclohexatriene that could readily undergo three olefin-type functionalizations and enable key retrosynthetic simplifications (Figure 1).

With the foregoing analysis in mind, we recognized that the development of a dearomatization process⁹ that would also result in desymmetrization of benzene¹⁰ was critical to our synthetic plan. We hypothesized that the application of visible-light-promoted *para*-cycloaddition of the N–N arenophile MTAD (**4**),¹¹ in combination with an aryl nucleophile (ArM) and transition metal catalysis (TM cat.), could provide *trans*-carboaminated product **6** (Figure 2). Specifically, the intermediate MTAD-benzene cycloadduct **5** could serve as a viable substrate for




Figure 2. Design of dearomative *trans*-carboamination sequence. oxidative addition due to its *bis*-allylic bridgehead positions bearing an electron-deficient urazole.¹² Mechanistically, we envisioned this catalytic process as commencing with π -coordination of the diene to the metal complex *anti* to the arenophile moiety (**5**→**I**). Subsequent oxidative addition should give cyclohexadienyl intermediate **II**, which should undergo transmetalation with an aryl metal reagent to form species **III**. This symmetric η^5 -complex can then undergo reductive elimination to deliver diene complex **IV**. Finally, diene decomplexation yields the product and regenerates the metal catalyst. The central feature of this design is the generation and capture of η^5 -cyclohexadienyl reactive intermediate; the desired 1,2-site-selectivity of the carboamination process would be favored because of the greater positive charge localized on the

termini of the η^5 -system.¹³ Though no catalytic processes involving cyclohexadienyl complexes exist to date, such outcomes are well preceded in cases wherein cationic cyclohexadienylmetal complexes react with nucleophiles in a stoichiometric fashion.¹⁴ Importantly, because of the symmetrical nature of the η^5 -intermediate **III**, a suitable chiral ligand bound to the metal center could enable enantiodiscrimination that involves the differentiation of the enantiotopic termini of the cyclohexadienyl system, forming the desired product in an enantioselective fashion.

On the basis of this design, we began our investigations into the dearomative carboamination. Accordingly, we found that nickel-based catalysts with bidentate ligands, in combination with aryl Grignard reagents, gave the best results (Figure 3). Specifically, we identified that conducting the MTAD-benzene cycloaddition reaction in dichloromethane, followed by the addition of a Ni-catalyst ([Ni(cod)₂]/dppf (**8**) = 10/20 mol%) and aryl Grignard reagent **7** delivered the desired dearomatized product **6** in 74% yield as a single constitutional and diastereoisomer. In addition, we performed a comprehensive evaluation of chiral bidentate ligands,¹⁵ and discovered that the PHOX-type ligand (*R,R*)-*i*Pr-Phosferrox (**9**) afforded desired product **6** in 75% yield and with high enantioselectivity (98:2 er).




Figure 3. MTAD-mediated, Ni-catalyzed dearomative *trans*-1,2-carboamination of benzene.

The enantioselective, dearomative *trans*-carboamination of benzene serves as the key strategic maneuver as it installs the first two vicinal stereocenters and drastically simplifies synthetic entry to the pancratistatin core (Figure 4). Early on, we found that masking the acidic urazole hydrazyl group ($pK_a = 5.8$ in water) is crucial for the precise orchestration of subsequent stereoselective manipulations. Therefore, we selected the methyl group as it could be introduced simply by quenching the dearomatization reaction with dimethyl sulfate (**3**→**10**). Moreover, on a preparative scale, we were able to lower the catalyst and ligand loadings to 5 and 10 mol% without significant erosion in yield or selectivity (65% yield, 98:2 er, after methylation quench). Thus, by simply executing this reaction in a one-liter media bottle with commercial-grade visible-light diodes we were able to conveniently prepare dearomatized compound **10** on a decagram scale. It is worth noting that using this protocol, we have prepared >300 g of this carboaminated product in total.

With the key diene intermediate **10** in hand, the focus then shifted to the next two olefin difunctionalization operations, which would introduce the remaining four hydroxy substituents in a stereoselective manner and complete the pancratistatin core. Because of the electron-withdrawing effect of the urazole nitrogen, the alkene distal to this moiety reacted preferentially with electrophilic reagents. Thus, a chemo- and diastereoselective preparation of *trans*-diol **11** was accomplished using a one-pot

protocol involving epoxidation with *m*CPBA and subsequent epoxide hydrolysis in the presence of *p*TsOH and a large excess of water.¹⁶ In addition, the use of hexafluoroisopropanol (HFIP) as the solvent was essential to obtain diol product **11** in 74% yield.¹⁷ Exposure of the remaining alkene in **11** to Upjohn dihydroxylation conditions¹⁸ provided tetraol **12** in 91% yield and as a single stereoisomer. Importantly, this step completes the trifold olefin difunctionalization sequence that transforms benzene into the fully decorated pancratistatin core, establishes all six contiguous stereocenters, and sets the stage for lactam construction. To this end, deprotection of urazole **12** to free amine **14** using conditions to effect hydrolysis and N–N bond cleavage proved challenging, as aggressively acidic or basic conditions led to complete decomposition of starting material. Therefore, we explored hydride-based reducing agents and found that treatment of **12** with LiAlH₄ could reduce the urazole; however, the resulting cyclic hydrazine hemiaminal **13** proved unstable, complicating its isolation and the overall reproducibility of this step. To overcome this hurdle, we decided to develop a one-pot protocol that directly reduced urazole **12** to amine **14** without handling the sensitive intermediate **13**. Thus, LiAlH₄ reduction, followed by aqueous quench and subsequent addition of Raney®-cobalt¹⁹ under a hydrogen atmosphere, gave the best results and provided free amine **14** in 60% yield. Noteworthy, using this sequence, we were able to prepare several grams of aminotetraol precursor **14** in a single pass.

The final step, needed to complete isocarbostyryl framework of the pancratistatins, namely the installation of the carbonyl group, was achieved in two steps comprising halogenation and intramolecular aminocarbonylation. To increase step economy and the overall efficiency of the synthesis²⁰ we probed reactions that could function on the unprotected aminotetraol **14**. After extensive investigation, this task was effectively accomplished using bromination (Br₂ in AcOH),²¹ followed by NaCo(CO)₄-catalyzed carbonylation under a CO atmosphere and UV light irradiation²² to give the corresponding (+)-7-deoxypancratistatin (**2**) in 72% yield over the two steps. Moreover, we were able to conduct both transformations in a single reaction vessel, without the need of isolation and purification of the bromide intermediate, making this formal carbonyl insertion operation more practical on a gram scale.

Though more than a dozen chemical syntheses of (+)-7-deoxypancratistatin (**2**) exist, its conversion to (+)-pancratistatin (**1**) through late-stage C-7 arene hydroxylation has never been established. We undertook this task by exploring directed ortho metalations and found that hydroxylation of position C-7 could be effected using a cupration/oxidation sequence²³; however, only when (+)-7-deoxypancratistatin (**2**) was persilylated with hexamethyldisilazane (HMDS).²⁴ According to control experiments (see Supplementary materials), this direct arene hydroxylation is likely to proceed through the intermediacy of tetra-*O*-silylated-(+)-7-deoxypancratistatin (**15**), which undergoes C-7 cupration with (TMP)₂Cu(CN)Li₂. Subsequent *in situ* oxidation with *t*BuOOH and acidic workup furnished (+)-pancratistatin (**1**) in 62% yield.

In summary, we have completed the syntheses of (+)-7-deoxypancratistatin (**2**) and (+)-pancratistatin (**1**) in six and seven operations in 19% and 12% overall yield. Importantly, using this synthetic blueprint, we have prepared several grams of natural products **1** and **2** to date. The synthetic efficiency of our approach originates from the development of an enantioselective, catalytic, dearomative *trans*-carboamination of benzene for which no chemical or biological equivalent exists. This transformation permits access to the key diene **10** and greatly simplifies the synthetic approach to the aminocyclitol core. Finally, by




Figure 4. Synthesis of (+)-pancratistatins (**1** and **2**) from benzene (**3**). Reagents and conditions: [1.] benzene (**3**), MTAD (**4**), CH_2Cl_2 , visible light, -78°C ; then $[\text{Ni}(\text{cod})_2]$ (**9**), (R,R_p) -*i*Pr-Phosferrox (**9**, 10 mol%), arylmagnesium bromide **7**, CH_2Cl_2 , THF, -78°C to rt; quench with Me_2SO_4 , K_2CO_3 , 65% (98:2 *er*). [2.] *m*CPBA, TsOH, CH_2Cl_2 , HFIP, H_2O , 50°C , 74%. [3.] NMO, OsO_4 (5 mol%), $t\text{BuOH}:\text{H}_2\text{O}$, rt, 91%. [4.] LiAlH_4 , THF, reflux; quench with Rochelle salt; then Raney[®]-Co, H_2 (1 atm), 60°C , 60%. [5.] Br_2 , AcOH, rt. [6.] $\text{NaCo}(\text{CO})_4$ (30 mol%), $n\text{Bu}_4\text{NBr}$, CO (1 atm), NaHCO_3 , H_2O , 1,4-dioxane, 365 nm light, 60°C , 72% over two steps. [7.] HMDS, I_2 (1 mol%), MeCN, 80°C ; then solvent removal and $(\text{TMP})_2\text{Cu}(\text{CN})\text{Li}_2$, THF, $-78^\circ\text{C} \rightarrow 0^\circ\text{C}$; then $t\text{BuOOH}$, THF, -78°C , 62%.

providing a chemical connection between (+)-7-deoxypancratistatin (**2**) and (+)-pancratistatin (**1**), this work also presents a notable departure from previous syntheses of the pancratistatins, in which each member required *de novo* synthesis using the properly C-7 functionalized aromatic starting material. We believe that the myriad opportunities in alkene functionalization should render the dearomative carboamination strategy amenable to the preparation of other natural products, as well as a diverse set of congeners.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Experimental procedures, as well as spectroscopic and analytical data for all new compounds (PDF)
Crystallographic data (CIF)

AUTHOR INFORMATION

Corresponding Author

sarlah@illinois.edu

Notes

The University of Illinois has filed a provisional patent on this work.

ACKNOWLEDGMENT

Financial support for this work was provided by the University of Illinois, the National Science Foundation (CAREER Award No. CHE-1654110), and the NIH/National Institute of General Medi-

cal Sciences (GM122891). D. S. is an Alfred P. Sloan Fellow. L. H. acknowledges the National Institute of General Medical Sciences (NIGMS)-NIH Chemistry-Biology Interface Training Grant and J. P. and U. K. thanks the German Research Foundation (DFG) for postdoctoral fellowships. We thank Profs. S. E. Denmark and P. J. Hergenrother (University of Illinois) for critical proofreading of this manuscript and W. R. Grace and Co. for a gift of Raney[®]-cobalt. We also thank Dr. D. Olson and Dr. L. Zhu for NMR spectroscopic assistance, Dr. D. L. Gray for X-ray crystallographic analysis assistance, and F. Sun for mass spectrometric assistance.

REFERENCES

- Pettit, G. R.; Gaddamidi, V.; Cragg, G. M. *J. Nat. Prod.* **1984**, *47*, 1018.
- Ghosal, S.; Singh, S. K.; Kumar, Y.; Srivastava, R. S. *Phytochem.* **1989**, *28*, 611.
- (a) Ingrassia, L.; Lefranc, F.; Mathieu, V.; Darro, F.; Kiss, R. *Trans. Oncol.* **2008**, *1*, 1. (b) Kornienko, A.; Evidente, A. *Chem. Rev.* **2008**, *108*, 1982. (c) Ghavre, M.; Froese, J.; Pour, M.; Hudlicky, T. *Angew. Chem., Int. Ed.* **2016**, *55*, 5642.
- (a) Pettit, G. R.; Gaddamidi, V.; Herald, D. L.; Singh, S. B.; Cragg, G. M.; Schmidt, J. M.; Boettner, F. E.; Williams, M.; Sagawa, Y. *J. Nat. Prod.* **1986**, *49*, 995. (b) Ma, D.; Pignatelli, C.; Tarade, D.; Gilbert, T.; Noel, M.; Mansour, F.; Adams, S.; Dowhayko, A.; Stokes, K.; Vshyvenko, S.; Hudlicky, T.; McNulty, J.; Pandey, S. *Sci. Rep.* **2017**, *7*, 42957.
- (a) Pettit, G. R.; Pettit III, G. R.; Backhaus, R. A. *J. Nat. Prod.* **1993**, *56*, 1682. (b) Griffin, C.; Hamm, C.; McNulty, J.; Pandey, S. *Cancer Cell Int.* **2010**, *10*, 1.
- Gabrielsen, B.; Monath, T. P.; Huggins, J. W.; Kefauver, D. F.; Pettit, G. R.; Groszek, G.; Hollingshead, M.; Kirsi, J. J.; Shannon, W. M.; Schubert, E. M.; DaRe, J.; Ugarkar, B.; Ussery, M. A.; Phelan, M. J. *J. Nat. Prod.* **1992**, *55*, 1569.

- (7) For pancratistatin syntheses, see: (a) Danishefsky, S.; Lee, J. Y. *J. Am. Chem. Soc.* **1989**, *111*, 4829. (b) Tian, X.; Hudlicky, T.; Königsberger, K. *J. Am. Chem. Soc.* **1995**, *117*, 3643. (c) Trost, B. M.; Pulley, S. R. *J. Am. Chem. Soc.* **1995**, *117*, 10143. (d) Hudlicky, T.; Tian, X.; Königsberger, K.; Maurya, R.; Rouden, J.; Fan, B. *J. Am. Chem. Soc.* **1996**, *118*, 10752. (e) Magnus, P.; Sebbat, I. K. *J. Am. Chem. Soc.* **1998**, *120*, 5341. (f) Rigby, J. H.; Maharroof, U. S. M.; Mateo, M. E. *J. Am. Chem. Soc.* **2000**, *122*, 6624. (g) Kim, S.; Ko, H.; Kim, E.; Kim, D. *Org. Lett.* **2002**, *4*, 1343. (h) Li, M.; Wu, A.; Zhou, P. *Tetrahedron Lett.* **2006**, *47*, 3707. (i) Dam, J. H.; Madsen, R. *Eur. J. Org. Chem.* **2009**, 4666. (j) Jung, Y.-G.; Kang, H.-U.; Cho, H.-K.; Cho, C.-G. *Org. Lett.* **2011**, *13*, 5890. (k) Cagide-Fagin, F.; Nieto-García, O.; Lago-Santomé, H.; Alonso, R. *J. Org. Chem.* **2012**, *77*, 11377. (l) Akai, S.; Kojima, M.; Yamauchi, S.; Kohji, T.; Nakamura, Y.; Sato, K.-i. *Asian J. Org. Chem.* **2013**, *2*, 299. (m) Potter, T. J.; Ellman, J. A. *Org. Lett.* **2017**, *19*, 2985.
- (8) For 7-deoxypancratistatin syntheses, see: (a) Paulsen, H.; Stubbe, M. *Tetrahedron Lett.* **1982**, *23*, 3171. (b) Keck, G. E.; McHardy, S. F.; Murry, J. A. *J. Am. Chem. Soc.* **1995**, *117*, 7289. (c) Tian, X.; Maurya, R.; Königsberger, K.; Hudlicky, T. *Synlett* **1995**, *11*, 1125. (d) Ref. 7d (e) Chida, N.; Jitsuoka, M.; Yamamoto, Y.; Ohtsuka, M.; Ogawa, S. *Heterocycles* **1996**, *43*, 1385. (f) Keck, G. E.; Wagner, T. T.; McHardy, S. F. *J. Org. Chem.* **1998**, *63*, 9164. (g) Akgün, H.; Hudlicky, T. *Tetrahedron Lett.* **1999**, *40*, 3081. (h) Aceña, J. L.; Arjona, O.; León, M. A.; Plument, J. *Org. Lett.* **2000**, *2*, 3683. (i) Håkansson, A. E.; Palmelund, A.; Holm, H.; Madsen, R. *Chem. Eur. J.* **2006**, *12*, 3243. (j) Zhang, H.; Padwa, A. *Tetrahedron Lett.* **2006**, *47*, 3905. (k) Nieto-García, O.; Lago-Santomé, H.; Cagide-Fagin, F.; Ortiz-Lara, J. C.; Alonso, R. *Org. Biomol. Chem.* **2012**, *10*, 825.
- (9) For recent reviews on dearomatizations, see: (a) Roche, S. P.; Porco, J. A. *Angew. Chem. Int. Ed.* **2011**, *50*, 4068. (b) Pouységu, L.; Deffieux, D.; Quideau, S. *Tetrahedron* **2010**, *66*, 2235. (c) Lewis, S. E. *Chem. Commun.*, **2014**, *50*, 2821. (d) Pape, A. R.; Kaliappan, K. P.; Kündig, E. P. *Chem. Rev.* **2000**, *100*, 2917.
- (10) For recent review on enantioselective dearomatizations, see: Zhuo, C.-X.; Zhang, W.; You, S.-L. *Angew. Chem. Int. Ed.* **2012**, *51*, 12662.
- (11) (a) Hamrock, S. J.; Sheridan, R. S. *J. Am. Chem. Soc.* **1989**, *111*, 9247. (b) Southgate, E. H.; Pospech, J.; Fu, J.; Holycross, D. R.; Sarlah, D. *Nat. Chem.* **2016**, *8*, 922.
- (12) For selected reviews of TM-catalyzed opening of oxo- and azabenzonorbornadienes, see: (a) Lautens, M.; Fagnou, K.; Hiebert, S. *Acc. Chem. Res.* **2003**, *36*, 48. (b) Rayabarapu, D. K.; Cheng, C.-H. *Acc. Chem. Res.* **2007**, *40*, 971. (c) Woo, S.; Keay, B. A. *Synthesis* **1996**, *6*, 669. (d) Chiu, P.; Lautens, M. *Top. Curr. Chem.* **1997**, *190*. For selected work, see: (e) Panteleev, J.; Menard, F.; Lautens, M. *Adv. Synth. Catal.* **2008**, *350*, 2893. (f) Lautens, M.; Ma, S. *J. Org. Chem.* **1996**, *61*, 7246.
- (13) Davies, S. G.; Green, M. L. H.; Mingos, D. M. P. *Tetrahedron* **1978**, *34*, 3047.
- (14) Pearson, A. J. *Acc. Chem. Res.* **1980**, *13*, 463.
- (15) See the Supporting Information for details regarding ligand examination.
- (16) For a review on the site-selective opening of vinyloxydes, see: Olofsson, B.; Somfai, P. in *Aziridines and Epoxides in Organic Synthesis*; Yudin, A. K., Eds.; Wiley-VCH: Weinheim, Germany, **2006**; p 315.
- (17) For the beneficial role of HFIP in epoxidation and epoxide opening reactions, see: (a) Berkessel, A.; Adrio, J. A. *J. Am. Chem. Soc.* **2006**, *128*, 13412. (b) Byers, J. A.; Jamison, T. F. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 16724.
- (18) VanRheenen, V.; Kelly, R. C.; Cha, D. Y. *Tetrahedron Lett.* **1976**, *17*, 1973.
- (19) Banwell, M. G.; Jones, M. T.; Reekie, T. A.; Schwartz, B. D.; Tan, S. H.; White, L. V. *Org. Biomol. Chem.* **2014**, *12*, 7433.
- (20) Newhouse, T.; Baran, P. S.; Hoffmann, R. W. *Chem. Soc. Rev.* **2009**, *38*, 3010.
- (21) Crude ¹H-NMR revealed an 8:1 ratio of constitutional isomers.
- (22) Brunet, J.-J.; Sidot, C.; Caubere, P. *J. Org. Chem.* **1983**, *48*, 1166.
- (23) Tezuka, N.; Shimojo, K.; Hirano, K.; Komagawa, S.; Yoshida, K.; Wang, C.; Miyamoto, K.; Saito, T.; Takita, R.; Uchiyama, M. *J. Am. Chem. Soc.* **2016**, *138*, 9166.
- (24) Karimi, B.; Golshani, B. *J. Org. Chem.* **2000**, *65*, 7228.

Insert Table of Contents artwork here

